Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
From the early months of the pandemic in 2020, it was clear that pregnant patients were at higher risk of maternal complications and adverse pregnancy outcomes.1 A meta-analysis including more than 100,000 pregnancies during the first year of the pandemic found a global increase in maternal death and stillbirth-but with the introduction of vaccinations came a decrease in overall morbidity and mortality from the disease.2,3 Here is what we have learned about pregnancy and COVID-19. Prone positioning is also safe and feasible in pregnancy with the aid of padding and pillows as needed.21 REMDESIVIR AND DEXAMETHASONE In patients who are hospitalized but do not require oxygen supplementation, treatment with remdesivir given 200 mg intravenously on day 1 followed by 100 mg daily for 5 days total (with extension to 10 days if no clinical improvement) is recommended. OTHER PHARMACOTHERAPIES Intravenous tocilizumab may be added to remdesivir and dexamethasone in pregnant patients with rapidly increasing oxygen needs and evidence of systemic inflammation.20 Tocilizumab is an IL-6 inhibitor that may decrease mortality in patients with COVID-19 and increased inflammatory markers.26 Lastly, oral baricitinib is a monoclonal antibody that may be used in select nonpregnant patients with severe disease, but because of limited pregnancy data, use in pregnant patients should be individualized. OUTPATIENT MANAGEMENT As pregnancy is a risk factor for severe disease, outpatient treatment maybe considered in select pregnant patients with higher risk for disease progression.